Bullfrog AI CEO highlights AI platform advances, LIBD collaboration, BF-114 progress, $8.83M raised in 2024

BullFrog AI Holdings, Inc.

bfLEAP platform enhanced with generative and causal AI exclusively licensed from Johns Hopkins APL, enabling explainable AI for target discovery and drug repositioning.
LIBD collaboration identified novel drug targets for schizophrenia, bipolar disorder, and major depressive disorder; advanced pharma discussions underway.
BF-114 demonstrated potential in obesity, MASLD, and HCC; published in Cell Reports. Liver disease market projected to exceed $36.5B by 2030.
Raised $8.83M from two equity offerings in 2024, bolstering cash position for growth initiatives and working capital.
Strengthened IP with Australian patent for BF-223 (oncology, glioblastoma); added Dr. Chittenden as CSO and Dr. Baldoni to SAB.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.